Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2021 08:00 ET | Source: KBP BioSciences

KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension

KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2 mm Hg with reduced hyperkalemia risk in the phase 2b studyArticle...
December 07, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients

KBP-5074 Achieves 10.1 mmHg reduction in systolic blood pressure (SBP) at 0.5mg dose compared to placebo Positive diastolic blood pressure (DBP) and Urine Albumin-to-Creatinine Ratio (UACR) Trends ...
November 18, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences Appoints Douglas Losordo Chief Medical Officer

PRINCETON, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the...
November 16, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences to Present at Upcoming Virtual Investor Conferences

PRINCETON, N.J., , Nov. 16, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the...
October 22, 2020 16:30 ET | Source: KBP BioSciences

KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting

PRINCETON, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
August 05, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074

KBP-5074 Being Evaluated for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) PatientsTop-Line Data on Track for Fourth Quarter of 2020 PRINCETON, N.J., Aug. 05,...
June 29, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension

KBP-5074 is a highly-selective non-steroidal mineralocorticoid receptor antagonist with potentially reduced hyperkalemia riskArticle published online; to be included in July 2020 print edition of...
May 21, 2020 08:35 ET | Source: KBP BioSciences

KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe Chronic Kidney Disease (CKD) patients with and without hemodialysis

Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or without hemodialysisOverall drug exposure was significantly lower in hemodialyzed patients vs....
May 20, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074

KBP-5074, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Under Evaluation for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) Patients Top Line Data...
April 28, 2020 08:00 ET | Source: KBP BioSciences

KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter baumannii

Potency demonstrated across geographically diverse strains including antibiotic-resistant isolates Data published online in Antimicrobial Agents and Chemotherapy PRINCETON, N.J., April 28, 2020 ...